KR20230116833A - Dr4 및/또는 dr5를 표적화하는 폴리펩티드 및 관련 조성물 및 방법 - Google Patents

Dr4 및/또는 dr5를 표적화하는 폴리펩티드 및 관련 조성물 및 방법 Download PDF

Info

Publication number
KR20230116833A
KR20230116833A KR1020237020902A KR20237020902A KR20230116833A KR 20230116833 A KR20230116833 A KR 20230116833A KR 1020237020902 A KR1020237020902 A KR 1020237020902A KR 20237020902 A KR20237020902 A KR 20237020902A KR 20230116833 A KR20230116833 A KR 20230116833A
Authority
KR
South Korea
Prior art keywords
ser
gly
leu
thr
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237020902A
Other languages
English (en)
Korean (ko)
Inventor
장-필리프 즬리앵
장-필리프 ?x리앵
디에스 에두르네 루하스
Original Assignee
더 호스피탈 포 식 칠드런
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 호스피탈 포 식 칠드런 filed Critical 더 호스피탈 포 식 칠드런
Publication of KR20230116833A publication Critical patent/KR20230116833A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020237020902A 2020-11-25 2021-11-25 Dr4 및/또는 dr5를 표적화하는 폴리펩티드 및 관련 조성물 및 방법 Pending KR20230116833A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063118306P 2020-11-25 2020-11-25
US63/118,306 2020-11-25
PCT/CA2021/051690 WO2022109743A1 (en) 2020-11-25 2021-11-25 Polypeptides targeting dr4 and/or dr5 and related compositions and methods

Publications (1)

Publication Number Publication Date
KR20230116833A true KR20230116833A (ko) 2023-08-04

Family

ID=81753696

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237020902A Pending KR20230116833A (ko) 2020-11-25 2021-11-25 Dr4 및/또는 dr5를 표적화하는 폴리펩티드 및 관련 조성물 및 방법

Country Status (9)

Country Link
US (1) US20240182544A1 (https=)
EP (1) EP4251654A4 (https=)
JP (1) JP2023550191A (https=)
KR (1) KR20230116833A (https=)
CN (1) CN116917339A (https=)
AU (1) AU2021386892A1 (https=)
CA (1) CA3202378A1 (https=)
MX (1) MX2023006148A (https=)
WO (1) WO2022109743A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240101550A9 (ko) * 2021-09-13 2025-12-10 더 호스피탈 포 식 칠드런 암 치료용 dr5-표적화 다중체
KR20250135167A (ko) * 2022-09-11 2025-09-12 래디언트 바이오테라퓨틱스 인크. 다중체를 사용하는 화학요법-내성 종양의 치료

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109195626B (zh) * 2015-10-30 2022-09-13 银河生物技术有限责任公司 结合死亡受体4和死亡受体5的抗体
WO2019023811A1 (en) * 2017-08-04 2019-02-07 The Hospital For Sick Children NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY
JP2022529512A (ja) * 2019-04-25 2022-06-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗体で修飾した自己集合するタンパク質ナノケージ（ｓａｐｎａ）及びその部分

Also Published As

Publication number Publication date
CN116917339A (zh) 2023-10-20
CA3202378A1 (en) 2022-06-02
AU2021386892A1 (en) 2023-06-22
JP2023550191A (ja) 2023-11-30
AU2021386892A9 (en) 2024-08-08
EP4251654A1 (en) 2023-10-04
MX2023006148A (es) 2023-08-07
US20240182544A1 (en) 2024-06-06
WO2022109743A1 (en) 2022-06-02
EP4251654A4 (en) 2024-11-27

Similar Documents

Publication Publication Date Title
KR102473964B1 (ko) T 세포 수용체
KR102434073B1 (ko) Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
JP2022543070A (ja) 多価及び多重特異性ナノ粒子プラットフォーム及び方法
KR20230136166A (ko) 멀타바디 구축물, 조성물, 및 방법
CN113728005A (zh) Cd3特异性结合分子
US11859001B2 (en) IL12RB1-Binding molecules and methods of use
KR20230083316A (ko) Sars-cov-2를 표적화하는 폴리펩티드, 및 관련 조성물 및 방법
US20250171548A1 (en) IL27RAlpha BINDING MOLECULES AND METHODS OF USE
KR20230116833A (ko) Dr4 및/또는 dr5를 표적화하는 폴리펩티드 및 관련 조성물 및 방법
US20230357414A1 (en) Il12rb2 binding molecules and methods of use
JP2023546269A (ja) Ｔ細胞を増殖させるための二重特異性コンストラクトおよび関連する方法
US20230279125A1 (en) Il28ra binding molecules and methods of use
RU2859397C2 (ru) МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ IL27Rα, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US20250011397A1 (en) Modified multabody constructs, compositions, and methods targeting sars-cov-2
US20250002564A1 (en) Modified multabody constructs, compositions, and methods
CN116615255A (zh) 靶向SARS-CoV-2的多肽及相关组合物和方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230621

Patent event code: PA01051R01D

Comment text: International Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20230628

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241125

Comment text: Request for Examination of Application